Please assess the completion status of the following clinical trial:

Trial Title: Therapy for Pediatric Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible patients must have histologically confirmed previously untreated Hodgkin's disease (Patients receiving limited emergent RT or steroid therapy because of cardiopulmonary decompensation or spinal cord compression will be eligible for protocol enrollment).~* Patients must be 21 years of age or younger~* Ann Arbor stages IIB-IV~* No prior treatment.~* No pregnant or lactating women.~* Signed informed consent~* If re-evaluation of a patient's disease shows favorable risk features or intermediate risk features, the patient will be removed from the HOD99 study and consented to the respective HOD08 or HOD05 study.~Inclusion: treatment of favorable risk features:~* Ann Arbor IA or IIA with:~  1. Non-bulky mediastinal disease (\<33% mediastinal to thoracic ratio on chest x ray)~ 2. Ann Arbor stage IA or IIA with any of the following features: (1) E lesions (s), (2) 3 or more nodal sites involved, (3) Bulky mediastinal adenopathy (mediastinal mass to thoracic cavity ratio 33% or greater by chest radiograph)~     Inclusion: unfavorable risk features:~* Stage must be classified as one of the following:~  1. Ann Arbor stage IIB, IIIB, or any IV

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Unfavorable Risk, Group 2 (Type: EXPERIMENTAL): Unfavorable risk, group 2 arm in patients with Hodgkin's disease (n=146)
- Favorable Risk (Type: EXPERIMENTAL): Favorable Risk arm in patients with Hodgkin's Disease (n=91).
- Intermediate Risk (Type: EXPERIMENTAL): Intermediate Arm in patients with Hodgkins's disease (n=46).
- Unfavorable Risk, Group 1 (Type: EXPERIMENTAL): Unfavorable risk group 1 closed early due to excessive number of adverse events (n=13).

Based on this trial design, predict the completion outcome and termination type (if applicable).